Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients

NCT03282643 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: Rivaroxaban 10 MG
DRUG: Rivaroxaban 20 MG
DRUG: Low-molecular-weight heparin

Sponsor

Capital Medical University